3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
69
Carcinoma, Intraductal, Noninfiltrating
9
Breast Carcinoma In Situ
6
Breast Neoplasms, Male
5
Neoplasms
3
Neoplasm Metastasis
3
Urinary Bladder Neoplasms
2
Inflammatory Breast Neoplasms
2
Sleep Wake Disorders
1
Risk Reduction Behavior
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Obesity
1
Newly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast Cancer
1
Mastodynia
1
Glioma
1
Fibrocystic Breast Disease
1
Fibroadenoma
1
Fatigue
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Disease Progression
1
Desmoid Tumors
1
Cystic Fibrosis
1
Cystadenocarcinoma, Serous
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Lobular
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Cancer Metastatic
1
Interventions
tusamitamab ravtansine
1
nirogacestat
1
exemestane
1
Tamoxifen
1
Letrozole
1
Gemcitabine
1
Fulvestrant
1
Docetaxel
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Breast Cancer Metastatic
×
Tamoxifen
×
Clear all
NCT04059484
2026-02-24
AMEERA-3
Sanofi
Phase 2
Terminated
367 enrolled
30 charts